| |
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
Today’s Big NewsOct 9, 2024 |
|
De-risk clinical trials with Foresight CLARITY’s ultra-sensitive MRD detection. Foresight CLARITY is IUO-ready for prospective trials through our CLIA-registered central lab. Learn more about Foresight CLARITY™️. 
|
|
| By Kevin Dunleavy GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S. |
|
|
|
By Nick Paul Taylor Boehringer Ingelheim has rolled into an alliance with undruggable target specialist Circle Pharma, putting together a package worth up to $607 million to secure the rights to a preclinical cancer program. |
By Zoey Becker Activist investor Starboard Value recently picked up a $1 billion stake in the drugmaker and will now pitch a strategy shift to top executives, the Financial Times reported. |
By Gabrielle Masson In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor designed to treat RSV in both kids and adults. |
|
Wednesday, October 16, 2024 | 2pm ET / 11am PT Join experts as they delve into the distinct strategies required for developing ADCs and RIT, focusing on how medical imaging can accelerate clinical trials and drug approval. Register now to gain practical insights into optimizing clinical trials and advancing cancer therapies through cutting-edge imaging techniques. 
|
|
By Fraiser Kansteiner Following the recent closure of its manufacturing facility in Marion, North Carolina, from flooding caused by Hurricane Helene, Baxter is providing some clarity on remediation timelines. |
By Darren Incorvaia A day after the Physics prize was given to two scientists for foundational work on machine learning, the Nobel Prize in Chemistry has been awarded to three scientists who used advanced computational methods to solve a decades-old problem. |
By Andrea Park Treatments for multiple sclerosis have long focused on slowing or stopping the acute disease process, which causes symptom relapses and visible changes on MRI scans. In recent years, however, researchers have defined a second, concurrent form of disease progression, dubbed “chronic smoldering.” |
By Fraiser Kansteiner Universal Cells—which Astellas refers to as its cell therapy research organization—is establishing a second location overseas at the Japanese pharma’s research campus in Tsukuba. As part of the move, 12 Universal roles in Seattle are being transferred to the Tsukuba site, while another 12 employees are being laid off. |
By Conor Hale Illumina bills the MiSeq i100 series as a complete redesign of its original MiSeq sequencer, which made its debut in 2011, saying it can operate four times faster and use room temperature reagents. |
By Kevin Dunleavy Clearside’s CLS-AX (axitinib injectable suspension) has aced a phase 2b trial, achieving its primary and secondary outcomes for patients with neovascular age-related macular degeneration (wet AMD). |
By Darren Incorvaia Though the peak of COVID-19 deaths is thankfully behind us, the virus is still a pernicious public health threat that vexes drugmakers by constantly evolving new variants that can elude existing treatments. |
By Conor Hale ShiraTronics' drug-free therapy system is designed for patients who have not seen relief with prescription drugs, with severe headaches occurring at least 15 days each month. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
|
|---|
|
|
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now. 
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
